Chonluten

Chonluten is a synthetic tripeptide made of three amino acids, glutamic acid, aspartic acid and glycine, so it is often shortened to EDG. Some sellers also list it under the code T-34. It belongs to the family of short peptide bioregulators that came out of Russian research, and its main target is the lung. That early research used lower doses over longer stretches. The higher-dose respiratory protocols that circulate now came later. Today it is a niche product, sold mostly as a lyophilized research peptide.

Most interest in Chonluten is about the lungs. People look at it for chronic airway conditions, mainly asthma, COPD and chronic bronchitis, which the research names as candidates for therapy or add-on use. Smokers, former smokers and older adults with declining lung function are the other main groups, since the clearest results came from aged or stressed tissue. Some people use it for acute problems such as recovery from a respiratory infection, often with a daily loading week at the start. It is sometimes stacked with other peptides people use for lung support, such as BPC-157 or TB-500. These are the reasons people try it. They are not proven outcomes.

Chonluten is not a drug that binds a receptor on the cell surface. It is described as a regulator of gene expression. In lung and bronchial epithelial cells it is proposed to act on chromatin and gene promoters, changing which genes the cell reads. The genes involved fall into three groups. Some drive inflammation, such as the cytokine genes. Some make antioxidant enzymes. Others control how cells multiply when inflammation hits. Its main activity is in the lungs, with secondary activity in the gastrointestinal tract. The most interesting claim is that it works best on tissue that has drifted from normal. Older and stressed models showed the strongest effects, which points to a peptide that restores balance more than one that stimulates healthy tissue.

Chonluten comes as a lyophilized powder that has to be reconstituted under sterile conditions. Community protocols give it as a subcutaneous injection. The most common pattern is 10 mg three times a week, and reported doses run 10 to 20 mg every other day or three times a week. Cycles usually last 20 to 30 days. For an acute respiratory problem some people dose daily for the first week, then move to the regular schedule. The original research leaned toward lower doses over longer periods, around 10 mg three times a week for one to two months, and some of it used 5 to 10 mg doses. Time of day does not seem to matter much, but consistency does. A standard 30 mg vial holds three 10 mg doses, about one week at three doses a week. None of these protocols comes from a clinical trial.

The evidence for Chonluten is preclinical, from lung disease models in animals and cell cultures. In models of chronic inflammation and lung damage it reduced inflammation, preserved the structure of the airway lining and restored markers of healthy respiratory tissue. Those results, together with its effects on cytokines, antioxidant enzymes and gene regulation, make it a candidate for asthma, COPD and chronic bronchitis. The benefits were larger in older or stressed systems. The protocols in circulation are community practice, not trial results. It is an interesting research peptide for airway health that still needs human data.

Chonluten is not approved by the FDA. In the United States it is sold as a research peptide for laboratory use, and sellers label it as not intended for human therapeutic use. Researchers working with it are expected to follow institutional, safety and regulatory rules for peptide research. It is listed under several names, including EDG, T-34 and its Glu-Asp-Gly sequence.